International Goals

 Achieve an “AIDS free generation” by accelerating prevention and treatment of HIV among infants and children. Bring to zero the number of tuberculosis (TB)-affected families facing catastrophic costs due to TB.

MPP’s Contribution

Work in partnership with international and non-governmental organisations to accelerate the development of HIV and TB formulations specifically adapted for children.

Paediatric HIV and tuberculosis (TB) are neglected diseases, due in large part to the dearth of appropriate formulations adapted for children of different ages and weight bands. Of the 2.1 million children living with HIV globally, only 43% are receiving life-saving antiretroviral therapy (ART). In 2016, an estimated one million children became ill with TB and 250,000 children died from the infection, including children with HIV-associated TB. [1]

The Medicines Patent Pool (MPP) is a partner in the Paediatric HIV Treatment Initiative to speed the development of fixed-dose combinations for children. The MPP also participates in other paediatric working groups such as the WHO-led Paediatric ARV Working Group (PAWG) and Paediatric ARV Drug Optimization (PADO).

The MPP has signed four royalty-free licensing agreements specifically for paediatric medicines to treat children of different age groups. Licences with ViiV Healthcare for abacavir and dolutegravir, with AbbVie for lopinavir/ritonavir and with Merck, Sharp & Dohme (MSD) for raltegravir allow generic manufacture for countries where 99% of children living with HIV in low- and middle-income countries reside. All of the MPP’s other licences allow sublicensees to manufacture treatments for paediatric use and waive royalties on paediatric sales.

In tuberculosis, the MPP has signed an important collaborative agreement with Otsuka with the goal of making delamanid, a new TB drug, more available to children infected with multidrug-resistant tuberculosis. In a memorandum of understanding with TB Alliance, both parties commit to exploring potential avenues of collaboration to ensure that appropriate and affordable formulations reach children in need.


[1] World Health Organization

This website uses cookies to ensure you get the best experience on our website. Learn More